Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Kathryn M Hastie | Robert W Cross | Stephanie S Harkins | Michelle A Zandonatti | Anatoliy P Koval | Megan L Heinrich | Megan M Rowland | James E Robinson | Thomas W Geisbert | Robert F Garry | Luis M Branco | Erica Ollmann Saphire
Cell | 2019

Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency. Each GPC-B antibody recognized an overlapping epitope involved in binding of two adjacent GPC monomers and preserved the prefusion trimeric conformation. Differences among GPC-antibody interactions highlighted specific residues that enhance neutralization. Using structure-guided amino acid substitutions, we increased the neutralization potency and breadth of these antibodies to include all major LASV lineages. The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.

Pubmed ID: 31398326

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: U19 AI115589
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI135995
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI132223
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI141251
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI104621
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI109762
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI142790
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI132244
  • Agency: NIGMS NIH HHS, United States
    Id: P41 GM103393

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.